Medical device firm Charter Medical has received European regulatory clearance for cryogenic stem cell containers.
The CE Mark means that Charter’s cryogenic storage containers for hematopoietic stem cells, the stem cells that form blood and immune cells, can now be marketed in Europe. The containers are designed for cryogenic storage, preservation and transfer of these cells. The containers are already in use by some customers in the United States.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Winston-Salem, North Carolina-based Charter Medical specializes in the collection, processing, storage and filtration of body fluids in medical device and bio-processing industries. Products include blood filtration devices, blood transfusion and single-use containers and products for biotechnology, pharmaceutical and diagnostic reagent manufacturing.
Charter is a subsidiary of Connecticut-based Lydall (NYSE:LDL), a maker of specialty engineered products and materials with more than $338 million in annual revenue. Charter falls within Lydall’s Life Sciences Vital Fluids division, a smaller business for Lydall. That business unit generated $10.9 million in revenue through the third quarter of 2011, down from $11.6 million compared to the first three quarters of 2010. But Lydall believes that this business unit offers opportunities to grow.
“I am pleased with the launch of this product into Europe, which represents a strategic growth opportunity for the Cell-Freeze product line,” Lydall CEO Dale Barnhart said in a statement. “It demonstrates our commitment to increase our presence globally in the biotech and cellular therapy markets.”
Snowflakes image from stock.xchng
